sEH-IN-24

Cat. No.: HY-183545: Data Sheet Handling Instructions
FAQs
Technical Support

sEH-IN-24 is an orally active soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 1.9 nM. sEH-IN-24 inhibits the pro-inflammatory cytokines TNF-α and IL-6. sEH-IN-24 exhibits anti-inflammatory effects and exerts analgesic activity in vivo. sEH-IN-24 prevents pancreatic edema, inflammation and parenchymal atrophy. sEH-IN-24 can be used for the research of acute pancreatitis.

For research use only. We do not sell to patients.

sEH-IN-24 Chemical Structure

CAS No. : 3121405-85-1

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

IL-6	sEH 1.9 nM (IC₅₀)

In Vitro

sEH-IN-24 (Compound (+)-34) (0.46-1000 nM) potently inhibits sEH with an IC₅₀ of 1.9 nM. It forms stable interactions with key active site residues and maintains dynamic stability when forming a complex with this enzyme^[1].
sEH-IN-24 exhibits low cytotoxicity against the normal cell lines 293-T, HL7702 and MIHA, with a GI₅₀ value >100 μM^[1].
sEH-IN-24 (0.25-8 μM) potently inhibits LPS-induced release of IL-6 and TNF-α in RAW 264.7 and THP-1 macrophages, with IC₅₀ values ranging from 0.7 to 1.3 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	C_max	AUC_0-24	T_1/2	T_max	V_d	CL	Bioavailability
Mice^[1]	20 mg/kg	p.o.	10127 ng/g	148683 ng·h/mL	/	/	/	/	/
Rat^[1]	20 mg/kg	p.o.	2064 ng/mL	17834 ng·h/mL	2.38 h	2.08 h	4017 mL/kg	1308 mL/h/kg	22.1 %
Rat^[1]	5 mg/kg	i.v.	7985 ng/mL	20144 ng·h/mL	2.21 h	0.09 h	896 mL/kg	273 mL/h/kg	/

In Vivo

sEH-IN-24 (5-20 mg/kg; p.o.; i.p.; single dose) exhibits sustained, dose-dependent anti-inflammatory activity in a mouse carrageenan-induced paw edema model, increasing plasma anti-inflammatory EET/DHET ratios with peak oral inhibition of 37.3% at 2 h post-administration^[1].
sEH-IN-24 (5-10 mg/kg; p.o.; single dose) demonstrates potent, dose-dependent oral analgesic activity in a mouse acetic acid-induced writhing model, reducing writhing episodes by 45% at the 10 mg/kg dose^[1].
sEH-IN-24 (10 mg/kg; i.p.; two doses at 0.5 h and 2.5 h post-first cerulein injection) exerts robust therapeutic activity in a mouse cerulein-induced acute pancreatitis model, reducing pancreatic histopathology scores by 56.3%, lowering pro-inflammatory cytokines, and increasing anti-inflammatory EET/DHET ratios in pancreatic tissue and plasma^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J (male, 23−25 g, 6−8 weeks old)^[1]
Dosage:	20 mg/kg (p.o.); 10 mg/kg (p.o.); 10 mg/kg (i.p.); 5 mg/kg (i.p.)
Administration:	p.o.; single dose; i.p.; single dose
Result:	Achieved a paw edema inhibition rate of 37.3% at 2 h post-administration, which remained stable at 31.6% 4 h post-peak efficacy. Increased plasma 8,9-EET/DHET by 219% and 14,15-EET/DHET by 274% relative to the model group, alongside elevations in 8,9-EET (81.1%) and 14,15-EET (108%) levels, and reductions in 8,9-DHET (17.3%) and 14,15-DHET (23.9%) levels at 20 mg/kg (p.o.). Increased plasma 8,9-EET/DHET by 315%, 11,12-EET/DHET by 198%, and 14,15-EET/DHET by 308% relative to the model group, alongside elevations in 8,9-EET (56.8%), 11,12-EET (60.4%), and 14,15-EET (121%) levels, and reductions in 8,9-DHET (50.0%), 11,12-DHET (18.9%), and 14,15-DHET (28.2%) levels at 10 mg/kg (i.p.).

Animal Model:	C57BL/6J (male, 23−25 g, 6−8 weeks old)^[1]
Dosage:	10 mg/kg; 5 mg/kg
Administration:	p.o.; single dose
Result:	Reduced the number of writhing episodes by 45% relative to the model group at 10 mg/kg (p.o.). Significantly reduced writhing episodes at 5 mg/kg (p.o.), with activity showing a concentration-dependent correlation.

Animal Model:	C57BL/6J (male, 23−25 g, 6−8 weeks old)^[1]
Dosage:	10 mg/kg
Administration:	i.p.; two doses at 0.5 h and 2.5 h post-first cerulein injection
Result:	Reduced total pancreatic histopathological scores by 56.3% relative to the model group, alleviating edema, inflammatory infiltration, and parenchymal atrophy. Reduced plasma TNF-α levels by 46.8% and IL-6 levels by 67.1% relative to the model group. Increased pancreatic tissue 8,9-EET/DHET by 424%, 11,12-EET/DHET by 1476%, and 14,15-EET/DHET by 2180% relative to the model group. Increased plasma 11,12-EET/DHET by 86% and 14,15-EET/DHET by 111% relative to the model group.

Animal Model:	C57BL/6J (male, 8 weeks old)^[1]
Dosage:	20 mg/kg
Administration:	p.o.; single dose
Result:	Achieved a plasma Cmax of 10,127 ng/mL and AUC0-24h of 148,683 h·ng/mL. Achieved a liver Cmax of 36,378 ng/g and AUC0-24h of 468,142 h·ng/g. Achieved a kidney Cmax of 27,061 ng/g and AUC0-24h of 306,849 h·ng/g. Achieved a brain Cmax of 1021 ng/g and AUC0-24h of 9127 h·ng/g. Tissue-to-plasma Cmax ratios were 3.59 (liver), 2.67 (kidney), and 0.101 (brain). Tissue-to-plasma AUC0-24h ratios were 3.15 (liver), 2.06 (kidney), and 0.061 (brain).

Animal Model:	Sprague-Dawley (SD) (male, 200 g)^[1]
Dosage:	20 mg/kg (p.o.); 5 mg/kg (i.v.)
Administration:	p.o.; single dose; i.v.; single dose
Result:	After oral administration, had a Tmax of 2.08 h, Cmax of 2064 ng/mL, AUC0-24h of 17834 h·ng/mL, half-life of 2.38 h, volume of distribution of 4017 mL/kg, systemic clearance of 1308 mL/h/kg, and bioavailability of 22.1%. After intravenous administration, had a Tmax of 0.09 h, Cmax of 7985 ng/mL, AUC0-24h of 20144 h·ng/mL, half-life of 2.21 h, volume of distribution of 896 mL/kg, and systemic clearance of 273 mL/h/kg.

Molecular Weight

485.61

Formula

C₂₈H₃₉NO₆

CAS No.

3121405-85-1

SMILES

CC([C@@H]1C2=C(OC3=C1C(C(C)(C(C3(C)C)=O)C)=O)C=C(C=C2OCCCN4CCOCC4)OC)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Sun JR, et al. Discovery, Synthesis of Myrtucommulone B Analogs as Soluble Epoxide Hydrolase Inhibitors and Their Biological Activities. J Med Chem. 2026;69(9):10240-10262.

sEH-IN-24 Related Classifications

Inflammation/Immunology

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

sEH-IN-243121405-85-1Epoxide HydrolaseInterleukin RelatedIL293-Tepoxyeicosatrienoic acidsTHP-1TNF-αsoluble epoxide hydrolaseRAW 264.7dihydroxyeicosatrienoic acidsMIHAHL7702IL-6Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *